- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05401734
Robot Assisted Gait Training in Persons With a Spinal Cord Injury
Over the past decade, RAGT has emerged as a promising method for improving ambulation after spinal cord injury (SCI). Early reports of this therapy were very promising, yet a recent study suggested that even though RAGT may improve locomotor ability in the acute SCI population, it appears less functional to more conventional forms of ambulation such as wheelchair propulsion.
What most of these studies have neglected to address, however, is the efficacy of RAGT as a therapeutic exercise intervention for the SCI population. Indeed, persons with SCI lead by definition a sedentary lifestyle. This reduced activity can lead to a variety of secondary health complications, including an increased risk for cardiovascular disease, spasticity, altered muscle composition and reduced joint range of motion (ROM), increased risk for pressure sores, reduced bone mineral density, increased risk for osteoporosis, and bladder and bowel dysfunction. In addition, psychological components such as body image, self-esteem, self-efficacy, psychological well-being and quality of life in general may be affected.
Consequently, before RAGT is dismissed as an expensive but perhaps not superior alternative to conventional rehabilitation strategies after SCI, the potential effect of this therapy on a variety of health-related outcomes needs to be considered, and the potential physiological and psychological benefits associated with this whole-body upright exercise therapy may justify its use in both the acute and chronic SCI populations. Several investigations have already indicated that regular exposure to RAGT results in some very significant health-related benefits that may decrease the aforementioned risk of secondary health complications. To our knowledge however, longitudinal effect studies in the SCI population have not yet been conducted, and further studies are needed to provide definitive evidence. It can be assumed that such insights may further optimize long-term health benefits, but also the cost-benefit ratio of RAGT. In addition, a detailed analysis of RAGT parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed, etc.) and the direct cardiovascular response (heart frequency, blood pressure, blood lactate concentration) to RAGT have not yet been conducted.
The purpose of this research project is therefore to investigate the longitudinal effect of RAGT on the psychological well-being (Quality of Life, pain, fatigue), independence in activities of daily living, muscular strength and joint range of motion (ROM), and bladder and bowel function in persons with SCI.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Over the past decade, RAGT has emerged as a promising method for improving ambulation after spinal cord injury (SCI). Early reports of this therapy were very promising, yet a recent study suggested that even though RAGT may improve locomotor ability in the acute SCI population, it appears less functional to more conventional forms of ambulation such as wheelchair propulsion.
What most of these studies have neglected to address, however, is the efficacy of RAGT as a therapeutic exercise intervention for the SCI population. Indeed, persons with SCI lead by definition a sedentary lifestyle. This reduced activity can lead to a variety of secondary health complications, including an increased risk for cardiovascular disease, spasticity, altered muscle composition and reduced joint range of motion (ROM), increased risk for pressure sores, reduced bone mineral density, increased risk for osteoporosis, and bladder and bowel dysfunction. In addition, psychological components such as body image, self-esteem, self-efficacy, psychological well-being and quality of life in general may be affected.
Consequently, before RAGT is dismissed as an expensive but perhaps not superior alternative to conventional rehabilitation strategies after SCI, the potential effect of this therapy on a variety of health-related outcomes needs to be considered, and the potential physiological and psychological benefits associated with this whole-body upright exercise therapy may justify its use in both the acute and chronic SCI populations. Several investigations have already indicated that regular exposure to RAGT results in some very significant health-related benefits that may decrease the aforementioned risk of secondary health complications. To our knowledge however, longitudinal effect studies in the SCI population have not yet been conducted, and further studies are needed to provide definitive evidence. It can be assumed that such insights may further optimize long-term health benefits, but also the cost-benefit ratio of RAGT. In addition, a detailed analysis of RAGT parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed, etc.) and the direct cardiovascular response (heart frequency, blood pressure, blood lactate concentration) to RAGT have not yet been conducted.
The purpose of this research project is therefore to investigate the longitudinal effect of RAGT on the psychological well-being (Quality of Life, pain, fatigue), independence in activities of daily living, muscular strength and joint range of motion (ROM), and bladder and bowel function in persons with SCI over a period of 2 years in several cohorts. We will measure every three months. Patients will be asked to fill in the questionnaires 3, 6 9, 12, 15, 18, 21 and 24 months after inclusion. Additionally the patients will we asked to fill in his medication intake in the follow-up system.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
Antwerp
-
Geel, Antwerp, Belgien, 2440
- Rekrutierung
- De Maesschalck Lieven
-
Kontakt:
- Lieven De Maesschalck
- Telefonnummer: 0479911974
- E-Mail: lieven.demaesschalck@thomasmore.be
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- SCI
- Bone density
Exclusion Criteria:
- osteoporosis
- length more than 2 meter
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Cohort 1
Approximately 10 persons with a SCI will be included in the study.
All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre.
The recruitment will be performed by word of mouth.
Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study.
Participation will be strictly voluntary
|
The measured variables include: Questionnaires
Measurements:
|
Cohort 2
Approximately 10 persons with a SCI will be included in the study.
All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre.
The recruitment will be performed by word of mouth.
Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study.
Participation will be strictly voluntary
|
The measured variables include: Questionnaires
Measurements:
|
Cohort 3
Approximately 10 persons with a SCI will be included in the study.
All participants are persons included in the RAGT program organized by the To Walk Again Postrehabilitation Centre.
The recruitment will be performed by word of mouth.
Participants utilizing the Eksoskeleton at the To Walk Again Postrehabilitation Centre will be asked if they are willing to participate in this study.
Participation will be strictly voluntary
|
The measured variables include: Questionnaires
Measurements:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
ROM (Range of Motion)
Zeitfenster: 3 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
3 months
|
ROM (Range of Motion)
Zeitfenster: 6 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
6 months
|
ROM (Range of Motion)
Zeitfenster: 9 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
9 months
|
ROM (Range of Motion)
Zeitfenster: 12 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
12 months
|
ROM (Range of Motion)
Zeitfenster: 15 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
15 months
|
ROM (Range of Motion)
Zeitfenster: 18 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
18 months
|
ROM (Range of Motion)
Zeitfenster: 21 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
21 months
|
ROM (Range of Motion)
Zeitfenster: 24 months
|
Range of Motion.
We measure the range of motion of the legs with a Goniometer every three months.
Our goal is to see if there is an improvement due to the robot asssited gait training
|
24 months
|
WHOQOL
Zeitfenster: 3 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 1 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
3 months
|
WHOQOL
Zeitfenster: 6 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 1 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
6 months
|
WHOQOL
Zeitfenster: 9 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 1 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
9 months
|
WHOQOL
Zeitfenster: 12 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 1 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
12 months
|
WHOQOL
Zeitfenster: 15 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 1 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
15 months
|
WHOQOL
Zeitfenster: 18 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 0 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
18 months
|
WHOQOL
Zeitfenster: 21 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 1 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
21 months
|
WHOQOL
Zeitfenster: 24 months
|
World Health Organization Qualitiy of Life Questionnaire - BREF (WHOQoL-BREF).
We are using the WHOQOL-Bref instrument (questionnaire).
The WHOQOL is a quality of life assessment developed by the WHOQOL Group with fifteen international field centres, simultaneously, in an attempt to develop a quality of life assessment that would be applicable cross-culturally.
WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.
It has 4 domains namely physical health, psychological health, social relationship and environment, and 2 individual subscales on overall quality of life and general health.
It can be self-administered and has good internal consistency (0.75-0.87).
The higher the score, the more QOL.
Each item is scored between 1 and 5.
This scores will be translated to a score between 0-100 based on the manual for the general score and each subdomain score.
This questionnaire will be filled in every three months by the patient.
|
24 months
|
IPA
Zeitfenster: 3 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
3 months
|
IPA
Zeitfenster: 6 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
6 months
|
IPA
Zeitfenster: 9 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
9 months
|
IPA
Zeitfenster: 12 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
12 months
|
IPA
Zeitfenster: 15 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
15 months
|
IPA
Zeitfenster: 18 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
18 months
|
IPA
Zeitfenster: 21 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
21 months
|
IPA
Zeitfenster: 24 months
|
Participation of daily life (IPA).
This is a valid and reliable questionnaire (Impact on participation and autonomy).
This questionnaire is based on the international classification of human functioning.
The goal of of this questionnaire is to have a clear image on the way your healthy status influences your abilities to live your life and how you experience this feeling.
This questionnaire consist of 32 items divided in 5 domains.
(Autonomy outside, family roll, autonomy inside, social relations, work and education).
Scores for each item are between 0 to 4. The lower the score the better; the higher the score the more barriers.
For each domain a mean score between 0 and 4 will be calculated.
|
24 months
|
Bowel and bladder function
Zeitfenster: 3 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
3 months
|
Bowel and bladder function
Zeitfenster: 6 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
6 months
|
Bowel and bladder function
Zeitfenster: 9 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
9 months
|
Bowel and bladder function
Zeitfenster: 12 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
12 months
|
Bowel and bladder function
Zeitfenster: 15 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
15 months
|
Bowel and bladder function
Zeitfenster: 18 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
18 months
|
Bowel and bladder function
Zeitfenster: 21 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
21 months
|
Bowel and bladder function
Zeitfenster: 24 months
|
We will use the Neurogenic Bowel Dysfunction score.
This valid and reliable questionnaire consist of 10 items.
The minimum score is 0 the maximum score is 47.
The higher the score, the more discomfort.
0-6: very less; Score 7-9: Minimal; Score 10-13: Moderate, Score 14+: severe.
For urinary we use the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol).
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It consists 20 items sore between 0-10).
19-76 overall score with greater values indicating increased impact on quality of life.
|
24 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Medication
Zeitfenster: 3 months
|
Use of medication.
We ask the patient to fill in an digital diary concerning medication intake.
We ask digital information in a format with: Name of the medication, number of intake, prescription or not, regular or extra, reason.
|
3 months
|
Medication
Zeitfenster: 6 months
|
Use of medication.
We ask the patient to fill in an digital diary concerning medication intake.
We ask digital information in a format with: Name of the medication, number of intake, prescription or not, regular or extra, reason.
|
6 months
|
Medication
Zeitfenster: 9 months
|
Use of medication.
We ask the patient to fill in an digital diary concerning medication intake.
We ask digital information in a format with: Name of the medication, number of intake, prescription or not, regular or extra, reason.
|
9 months
|
Medication
Zeitfenster: 12 months
|
use of medication.
We ask the patient to fill in an diary concerning medication.
|
12 months
|
Medication
Zeitfenster: 15 months
|
Use of medication.
We ask the patient to fill in an digital diary concerning medication intake.
We ask digital information in a format with: Name of the medication, number of intake, prescription or not, regular or extra, reason.
|
15 months
|
Medication
Zeitfenster: 18 months
|
Use of medication.
We ask the patient to fill in an digital diary concerning medication intake.
We ask digital information in a format with: Name of the medication, number of intake, prescription or not, regular or extra, reason.
|
18 months
|
Medication
Zeitfenster: 21 months
|
Use of medication.
We ask the patient to fill in an digital diary concerning medication intake.
We ask digital information in a format with: Name of the medication, number of intake, prescription or not, regular or extra, reason.
|
21 months
|
Medication
Zeitfenster: 24 months
|
Use of medication.
We ask the patient to fill in an digital diary concerning medication intake.
We ask digital information in a format with: Name of the medication, number of intake, prescription or not, regular or extra, reason.
|
24 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- S58158
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur SCI - Rückenmarksverletzung
-
University of VersaillesBeendetZentrales Rückenmarksyndrom | Zentrales Cord Injury-SyndromFrankreich
-
Seoul National University HospitalAbgeschlossenUrologische Verschlechterung beim sekundären Tethered-Cord-Syndrom und Hinweise auf dessen ErkennungNeurogene Blasen | Tethered-Spinal-Cord-Syndrom
Klinische Studien zur Observation and follow up measurement
-
Istanbul University - Cerrahpasa (IUC)AbgeschlossenUnfruchtbarkeit | Psychische Belastung | Unfruchtbarkeit, weiblich | Depressionen, Angst | Die Rolle der KrankenschwesterTruthahn
-
University of UtahStanford UniversityAbgeschlossen
-
Assistance Publique - Hôpitaux de ParisAbgeschlossen
-
University College of AntwerpKU Leuven; University Hospital, Antwerp; Universiteit AntwerpenUnbekannt
-
VA Eastern Colorado Health Care SystemNoch keine Rekrutierung
-
Assiut UniversityRekrutierungAnomalien des Müller-GangsÄgypten
-
Shanghai 10th People's HospitalNoch keine Rekrutierung
-
Helse FordeRekrutierungArthritis, Rheuma | Psoriasis-Arthritis | SpondyloarthritisNorwegen
-
WepromIncyte Corporation; Resilience CareNoch keine RekrutierungDiffuses großzelliges B-Zell-LymphomFrankreich
-
University Hospital, Clermont-FerrandRekrutierungOsteoporose, postmenopausalFrankreich